Non-Invasive Prenatal Testing Market

Overview

The global Non-Invasive Prenatal Testing (NIPT) market was valued at USD 5.4 billion in 2025 and is projected to reach USD 16.5 billion by 2034, growing at a CAGR of 13.2% during the forecast period (2026-2034). The market growth is driven by rising maternal age and pregnancy-related risks, growing preference for non-invasive prenatal screening, increasing awareness of early fetal health assessment, expanding adoption of advanced genomic testing technologies. The market is shifting from a specialist test offered mainly to older or higher-risk pregnant women toward a routine, first-line screening option offered to all pregnancies, supported by professional guideline changes and falling per-test sequencing costs. Government initiatives such as China's Hebei Model, a provincial free NIPT screening program launched in 2019 that had screened more than two million pregnant women by 2025 with satisfaction rates above 99%, and the UK NHS Fetal Anomaly Screening Programme's 2021 rollout of NIPT for higher-chance pregnancies, are expanding public-sector access to cfDNA screening and building a template that other national health systems are evaluating for their own maternal-screening pathways. By region, North America held the largest share of the market in 2025, supported by broad professional-society guideline support, high private-insurance coverage rates, and a concentrated base of large reference laboratories. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by rising birth rates in parts of the region, expanding private healthcare and insurance coverage, and government-backed screening programs in China, together with growing adoption in Japan, South Korea, and India.

Market Size & Share

Market Dynamics

KEY MARKET TREND

AI-Enabled Bioinformatics and Enhanced Sequencing Chemistries Emerging as a Transformational Trend

• Laboratories and test developers are combining improved molecular chemistries with machine-learning-based bioinformatics pipelines to reduce "no-call" results at low fetal DNA fraction, allowing more patients to receive an actionable result from their first blood draw instead of being asked to redraw or referred for further testing.
• NGS platform vendors continue to invest in automated, sample-to-report workflows and multi-flow-cell sequencing architecture, shortening turnaround time and allowing laboratories to batch low-volume runs more flexibly without sacrificing throughput.
• Test menus are broadening from the three common trisomies to include selected microdeletion syndromes and additional chromosomal regions within a single NGS-based assay, widening the clinical scope of routine screening.
• Natera's enhanced Panorama NIPT, built on newly launched SNP-informed deep sequencing technology, achieved 100% sensitivity for trisomy 21 and trisomy 13 and reduced the no-call rate to 0.5% in a prospective, blinded validation study of 3,323 pregnancies, including 242 low fetal-fraction samples, according to the company's 2026 announcement.

KEY MARKET DRIVER

Expanding Insurance Coverage and Professional Guideline Support Driving Broader NIPT Adoption

• Rising maternal age continues to expand the eligible screening population, since the risk of fetal chromosomal abnormality increases with age and a growing share of births now occur to women in their mid-to-late thirties and older across developed markets.
• Government-backed public screening pathways, such as the NHS Fetal Anomaly Screening Programme's 2021 operational rollout of NIPT in England for higher-chance pregnancies, are extending publicly funded access to cfDNA screening beyond private-pay and privately insured patients.
• Technology and workflow improvements, including automated library preparation and benchtop sequencing and amplification platforms, are lowering the capital and per-test cost of offering NIPT, supporting adoption by smaller hospital and regional laboratories.
• According to ACOG, approximately 80% of insured patients in the United States are currently covered for NIPT regardless of risk, and coverage is close to universal for high-risk pregnancies, although coverage under some state Medicaid programs and private plans still varies.

KEY MARKET OPPORTUNITY

Expansion of Extended Fetal Risk and Carrier-Adjacent Panels Creating New Revenue Streams

• Test developers are extending cfDNA-based screening beyond aneuploidy into single-gene recessive and X-linked conditions, creating a new sub-segment of fetal-risk screening that complements, rather than replaces, traditional carrier screening.
• Large parts of India, Southeast Asia, Latin America, and the Middle East remain under-penetrated because of test affordability, leaving room for lower capital-cost platforms such as digital PCR and isothermal amplification to expand access outside large reference laboratories.
• Public screening programs such as China's Hebei Model and the UK's NHS FASP rollout demonstrate a scalable, government-financed access model that private test developers and laboratory networks can partner into for incremental test volume.
• BillionToOne's expanded UNITY Fetal Risk Screen, launched in May 2025, assesses fetal risk for up to 14 recessive and X-linked conditions from a single maternal blood sample without requiring a partner sample, extending cfDNA-based screening to populations, including Ashkenazi Jewish and pan-ethnic communities, that are not well served by standard aneuploidy-only panels. 

Non-Invasive Prenatal Testing Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Product

Consumables held the largest share of the market in 2025, because every NIPT procedure, regardless of the underlying platform, consumes assay kits, library-preparation reagents, and sequencing consumables on a recurring per-test basis. As global test volumes rise, laboratories place repeat consumable orders far more frequently than they purchase new instruments, giving this category a steady, high-visibility revenue base that is closely tied to birth rates and screening-uptake rates rather than to one-time capital budgets.

Instruments and systems, and in particular next-generation sequencing (NGS) platforms, are projected to grow at the fastest rate during the forecast period, supported by continued laboratory investment in automated, sample-to-report NGS systems that reduce turnaround time and manual handling. As more hospital and regional laboratories bring testing in-house rather than sending samples to reference laboratories, demand for compact, validated sequencing and amplification instruments is expected to rise faster than the market overall.

Product categories include

• Reagent Kits (Dominating Segment)
• Instruments & Systems (Highest CAGR Segment)
• Software

Analysis by Technology

Next-generation sequencing (NGS) held the largest share of the market in 2025, supported by its high accuracy across trisomies, sex chromosome aneuploidies, and expanding microdeletion panels, and by its established base of validated, CE-IVD and laboratory-developed assays at large reference laboratories. NGS platforms from established sequencing vendors continue to be the reference technology against which newer amplification-based methods are clinically validated.

Rolling circle amplification (RCA) and other isothermal amplification technologies are projected to grow at the fastest rate during the forecast period, because they avoid the thermal cyclers and capital-intensive sequencing infrastructure that NGS requires, lowering the cost of entry for smaller and decentralized laboratories, particularly in Latin America and parts of Asia where power stability and capital budgets can constrain NGS adoption. Published concordance studies comparing RCA-based and NGS-based trisomy 21 detection have reported agreement above 98%, supporting clinical confidence in these lower-cost platforms.

Technology categories include

• Next-Generation Sequencing - NGS (Dominating Segment)
• Rolling Circle Amplification (Highest CAGR Segment)
• Digital PCR
• Microarray
• Others

Analysis by Test Type

Trisomy testing, covering trisomy 21, trisomy 18, and trisomy 13, held the largest share of the market in 2025, reflecting the fact that screening for these three conditions remains the primary, guideline-endorsed reason NIPT is offered in routine prenatal care and the core validated indication across nearly every commercial NIPT panel worldwide. Continued integration of trisomy screening into routine prenatal workflows is expected to sustain demand for these tests.

Microdeletion syndrome testing is projected to grow at the fastest rate during the forecast period, supported by the expansion of NGS-based panels capable of detecting clinically significant microdeletions alongside standard aneuploidy screening, and by rising clinician and patient awareness of expanded prenatal genetic screening options beyond the common trisomies. Rising awareness among clinicians and expectant parents of expanded prenatal genetic screening options beyond common trisomies is further supporting demand for these tests.

Test Type categories include

• Trisomy Testing - T21, T18, T13 (Dominating Segment)
• Microdeletion Syndrome Testing (Highest CAGR Segment)
• Sex Chromosome Aneuploidy Testing
• Rh Factor
• Others

Analysis by End User

Hospitals held the largest share of the market in 2025, supported by their role as the first point of contact for prenatal care, integrated obstetric and genetic-counseling services, and established relationships with reference laboratories and test developers for sample collection and result delivery. The availability of specialized maternal-fetal medicine departments and access to follow-up diagnostic services further strengthen the adoption of non-invasive prenatal testing in hospital settings.

Diagnostic laboratories are projected to grow at the fastest rate during the forecast period, as independent laboratory networks continue to expand direct-to-provider testing menus, invest in in-house NGS and amplification platforms, and add capacity to serve smaller hospitals and specialty clinics that do not run NIPT on-site. Increasing investments in in-house next-generation sequencing and amplification platforms, along with expanded testing capacity for smaller hospitals and specialty clinics without on-site NIPT capabilities, are further driving segment growth.

End User categories include

• Hospitals (Dominating Segment)
• Diagnostic Laboratories (Highest CAGR Segment)
• Specialty Clinics
• Others

By Region

Non-Invasive Prenatal Testing Market Share 2025, (%)

North America

40%

South America

xx%

Europe

xx%

Middle East Africa

xx%

Asia Pacific

27%

North America held the largest market share in 2025, accounting for 40% of the global market, supported by strong professional-society guideline backing from ACOG and SMFM, high private-insurance coverage of NIPT regardless of risk, and a concentrated base of large reference laboratories and test developers, including Natera, Labcorp, Illumina, and Quest Diagnostics. The United States was the largest country market in the region in 2025, driven by high adoption of NIPT across prenatal care pathways, broad laboratory infrastructure, and established reimbursement coverage, while Canada is witnessing growing adoption supported by provincial public-health screening pathways. Mexico represents an emerging market supported by improving access to prenatal screening, expansion of private healthcare services, and increasing awareness of advanced genetic testing. Competitive intensity across North America remains high, with continued product-menu expansion, laboratory-network consolidation, and new-entrant activity from single-gene and carrier-adjacent test developers.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by large annual birth volumes, expanding private healthcare and insurance coverage across China, India, Japan, and South Korea, and government-backed public screening initiatives such as China's Hebei Model free NIPT program. China represented the largest country market in the region in 2025, supported by high testing volumes, expanding genomic testing infrastructure, and the presence of domestic companies such as BGI Genomics and Berry Genomics. India is expected to be the fastest-growing country market, driven by rising awareness of prenatal genetic screening, expansion of private diagnostic networks, increasing healthcare expenditure, and growing availability of NIPT through companies such as MedGenome and Neuberg Diagnostics. Japan and South Korea are supported by advanced healthcare systems, established prenatal screening practices, and increasing adoption of non-invasive genetic testing, while the Rest of Asia-Pacific is expected to benefit from gradual improvements in healthcare infrastructure, diagnostic accessibility, and awareness of prenatal genomic testing.

Countries and Regions Covered

North America (Largest Region)          

• United States (Largest Country Market)     
• Mexico
• Canada

Asia-Pacific (Fastest-Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market) 
• Japan
• South Korea
• Rest of Asia-Pacific

Europe

• Germany (Largest Country Market)
• United Kingdom
• France
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile
• Rest of Latin America

Middle East & Africa

• Saudi Arabia
• UAE (Largest Country Markets)
• Rest of Middle East & Africa

Market Share

The market is consolidated at the global level, with a small group of large diagnostics and genomics companies, including Illumina, Natera, Laboratory Corporation of America Holdings (Labcorp), F. Hoffmann-La Roche, BGI Genomics, Thermo Fisher Scientific, QIAGEN, Myriad Genetics, and Revvity, accounting for a substantial share of global test volume through proprietary next-generation sequencing platforms, large reference-laboratory networks, and established payer relationships. At the same time, the market remains moderately fragmented at the regional level, with numerous specialized laboratories and regional genomics companies, such as Berry Genomics, Annoroad Gene Technology, and GeneMind Biosciences in China; MedGenome and Neuberg Diagnostics in India; Gene Solutions in Vietnam; and Igenomix in Europe, competing on price, turnaround time, test accuracy, and local clinical relationships. Leading companies are prioritizing test-menu expansion into microdeletion and single-gene screening, platform automation, geographic expansion into under-penetrated Asia-Pacific and Latin American markets, and continued strategic partnerships and acquisitions to add genetic-testing capabilities, proprietary technologies, and laboratory capacity.

Key Players

• Illumina, Inc. (United States)
• Natera, Inc. (United States)
• Thermo Fisher Scientific Inc. (United States)
• QIAGEN N.V. (Netherlands)
• Myriad Genetics, Inc. (United States)
• Revvity, Inc. (United States)
• Fulgent Genetics, Inc. (United States)
• BillionToOne, Inc. (United States)
• Eone Diagnomics Genome Center (EDGC), Inc. (South Korea)
• GeneMind Biosciences Co., Ltd. (China)
• Annoroad Gene Technology (Beijing) Co., Ltd. (China)
• Berry Genomics Co., Ltd. (China)
• Gene Solutions JSC (Vietnam)
• NIPD Genetics Public Company Limited (Cyprus)
• IdentifAI Genetics (Israel)

Recent Market Developments

• February 2025: Yourgene Health launched the IONA Care+ non-invasive prenatal testing (NIPT) service in the United Kingdom, offering comprehensive screening for genetic conditions, including microdeletions.
• June 2025: BGI Genomics and Prom-Test Laboratories launched the first localized NIPT project in Armenia, enabling local delivery of the NIFTY® prenatal screening test following technology transfer.
• January 2026: Natera launched the 21-gene Fetal Focus single-gene NIPT, expanding non-invasive prenatal screening for inherited conditions using its LinkedSNP technology.
• May 2026: BillionToOne launched Unity Confirm, a non-invasive prenatal test designed to confirm high-risk screening results by capturing intact circulating fetal cells.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is Non-Invasive Prenatal Testing?

2

What is the CAGR of the NIPT Market?

3

Which product/service category leads the NIPT Market?

4

Which end user dominates the NIPT Market?

5

Which technology has the highest market share?

6

What are the latest trends in the NIPT Market?

7

Who are the end users of NIPT?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates